Drug Profile

Neltependocel - Aurion Biotech

Alternative Names: AURN-001; HCEC-1; Human corneal endothelial cell therapy - Aurion Biotech; Vyznova

Latest Information Update: 23 Jul 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kyoto Prefectural University of Medicine
Developer Aurion Biotech
Class Cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Corneal disorders

Most Recent Events

23 Jul 2025 Phase-III clinical trials in Corneal disorders in Canada, USA (Intraocular) (Aurion Biotech pipeline, July 2025)
23 Jul 2025 Aurion Biotech plans clinical development of neltependocel in European Union (Aurion Biotech pipeline, July 2025)
26 Mar 2025 Aurion Biotech plans a phase III trial for Corneal disorders in USA in the second half of 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com